Type 2 diabetes mellitus and its complications are associated with oxidative stress and the depletion of antioxidant defenses. The influence of acetylsalicylic acid on reversing the decrease in antioxidants, insulin resistance, glucose homeostasis, and inflammatory cascade can help prevent diabetes complications. Purpose: The aim of the study was to evaluate the effect of acetylsalicylic acid on the antioxidant enzymatic system in patients with diabetes. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in 21 patients of both sexes with Type 2 diabetes for less than five years at the time of diagnosis, without pharmacological treatment, and randomly selected. Acetylsalicylic acid (300 mg) was administered orally for three months to the study group (n = 11) compared to the placebo control group (n = 10). Before and after the intervention, anthropometric and metabolic measurements were taken, fasting plasma glucose, glycated hemoglobin A1c, lipid profile panel, glutathione peroxidase, superoxide dismutase, catalase, and antioxidant capacity/activity were determined; values are presented as mean ± standard deviation. Intra- and intergroup differences were tested by Wilcoxon signed rank and Mann-Whitney U test, respectively; p-value ≤ 0.05 was considered statistically significant. Results: The acetylsalicylic acid group showed a decrease in weight (85.6 ± 19.3 vs. 84.1 ± 19.0 kg p = 0.01), cholesterol (205.9 ± 16.6 vs. 186.0 ± 23.2 mg/dL p = 0.02), and glycated hemoglobin A1c (7.8% ± 0.9% vs. 7.0% ± 0.7% p = 0.02). The placebo group exhibited reduction in weight (76.1 ± 14.9 vs. 74.9 ± 15.0 kg p = 0.04), glycated hemoglobin A1c (6.9% ± 0.6% vs. 6.2% ± 0.4% p = 0.004), and total antioxidant capacity (4.1 ± 0.5 vs. 4.8 ± 0.3 mmol/L p = 0.002). Conclusion: The administration of acetylsalicylic acid did not modify the antioxidant enzyme system.
References
[1]
Khalid, M., Petroianu, G. and Adem, A. (2022) Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules, 12, Article No. 542. https://doi.org/10.3390/biom12040542
[2]
Darenskaya, M.A., Kolesnikova, L.I. and Kolesnokov, S.I. (2021) Oxidative Stress: Pathogenic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction. Bulletin of Experimental Biology and Medicine, 171, 179-189. https://doi.org/10.1007/s10517-021-05191-7
[3]
Zatalia, St. R. and Sanusi, H. (2013) The Role of Antioxidants in the Pathophysiology, Complications, and Management of Diabetes Mellitus. The Indonesian Journal of Internal Medicine, 45, 141-147.
[4]
Yaribeygi, H., Sathyapalan, T., Atkin, L.T. and Sahebkar, A. (2020) Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 8609213. https://doi.org/10.1155/2020/8609213
[5]
Ighodaro, O.M. (2018) Molecular Pathways Associated with Oxidative Stress in Diabetes Mellitus. Biomedicine & Pharmacotherapy, 108, 656-662. https://doi.org/10.1016/j.biopha.2018.09.058
[6]
Zatalia, S.R. and Sanusi, H. (2013) The Role of Antioxidants in the Pathophysiology, Complications, and Management of Diabetes Mellitus. The Indonesian Journal of Internal Medicine, 45, 141-147.
[7]
Cruz, H.J., Licea, M.E., Hernandez, G.P., Abraham, M.E. and Yanes, Q.M. (2011) Estrés oxidativo y diabetes mellitus. Revista Mexicana de Patología Clínica y Medicina de Laboratorio, 58, 4-15. http://www.medigraphic.com/patologiaclinica
[8]
Newsholme, P., Rebelato, E., Abdulkader, F., Krause, M., Carpinelli, A. and Curi, R. (2012) Reactive Oxygen and Nitrogen Species Generation, Antioxidant Defenses, and β-Cell Function: A Critical Role for Amino Acids. Journal of Endocrinology, 214, 11-20. https://doi.org/10.1530/JOE-12-0072
[9]
Galecki, P., Szemraj, J., Bieńkiewicz, M., Zboralski, K. and Gałecka, E. (2009) Oxidative Stress Parameters after Combined Fluoxetine and Acetylsalicylic Acid Therapy in Depressive Patients. Human Psychopharmacology: Clinical and Experimental, 24, 277-286. https://doi.org/10.1002/hup.1014
[10]
Lapshina, E.A., Sudnikovich, E.J., Maksimchik, J.Z., Zabrodskaya, S.V., Zavodnik, L.B., Kubyshin, V.L., Nocun, M., Kazmierczak, P., Dobaczewski, M., Watala, C. and Zavodnik, I.B. (2006) Antioxidative Enzyme and Glutathione-S-Transferase Activities in Diabetic Rats Exposed to Long-Term Aspirin Treatment. Life Sciences, 79, 1804-1811. https://doi.org/10.1016/j.lfs.2006.06.008
[11]
Baltazar, M.T., Dinis-Oliveira, R.J., Duarte, J.A., Bastos, M.L. and Carvalho, F. (2011) Antioxidant Properties and Associated Mechanisms of Salicylates. Current Medicinal Chemistry, 18, 3252-3264. https://doi.org/10.2174/092986711796391552
[12]
Caballero, F., Gerez, E., Batlle, A. and Vazquez, E. (2000) Preventive Aspirin Treatment of Streptozotocin Induced Diabetes: Blockage of Oxidative Status and Revertion of Heme Enzymes Inhibition. Chemico-Biological Interactions, 126, 215-225. https://doi.org/10.1016/S0009-2797(00)00168-X
[13]
Diario Oficial de la Federación (DOF) (n.d.) Norma Oficial Mexicana NOM-004-SSA3-2012, Del expediente clinico. https://dof.gob.mx/nota_detalle_popup.php?codigo=5272787
Jeyaseelan, L. and Rao, P.S. (1989) Methods of Determining Samples Size in Clinical Trials. Indian Pediatr, 26, 115-121.
[16]
Goldfine, A.B., Silver, R., Aldhahi, W., Cai, D., Tatro, E., Lee, J. and Shoelson, S.E. (2008) Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes. Clinical and Translational Science, 1, 36-43. https://doi.org/10.1111/j.1752-8062.2008.00026.x
[17]
Tmavská, Z.T.K. (1983) Sex Differences in the Pharmacokinetics of Salicylates. European Journal of Clinical Pharmacology, 25, 679-682. https://doi.org/10.1007/BF00542358
[18]
Elliot Cham, B., Dykman, J.H. and Bochner, F. (1982) Urinary Excretion of Aspirin. British Journal of Clinical Pharmacology, 14, 562-564. https://doi.org/10.1111/j.1365-2125.1982.tb02030.x
[19]
Hanley, M.J., Abernethy, D.R. and Greenblatt, D.J. (2010) Effect of Obesity on the Pharmacokinetics of Drugs in Humans. Clinical Pharmacokinetics, 49, 71-87. https://doi.org/10.2165/11318100-000000000-00000
[20]
Bordeaux, B.C., Qayyum, R. and Yanek, L.R. (2010) Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin. Preventive Cardiology, 13, 56-62. https://doi.org/10.1111/j.1751-7141.2009.00058.x
[21]
Blakytny, R. and Harding, J.J. (1992) Prevention of Cataract in Diabetic Rats by Aspirin, Paracetamol (Acetaminophen) and Ibuprofen. Experimental Eye Research, 54, 509-518. https://doi.org/10.1016/0014-4835(92)90129-G
[22]
Coudray, C. and Favier, A. (2000) Determination of Salicylate Hydroxylation Products as an in Vivo Oxidative Stress Marker. Free Radical Biology and Medicine, 29, 1064-1070. https://doi.org/10.1016/S0891-5849(00)00403-2
[23]
Ames, P.R., Batuca, J.R., Muncy, I.J., De La Torre, I.G., Pascoe-Gonzales, S., Guyer, K., Matsuura, E. and Lopez, L.R. (2012) Aspirin Insensitive Thromboxane Generation Is Associated with Oxidative Stress in Type 2 Diabetes Mellitus. Thrombosis Research, 130, 350-354. https://doi.org/10.1016/j.thromres.2012.03.025
[24]
Lemkes, B.A., Bähler, L., Kamphuisen, P.W., Stroobants, A.K., Van Den Dool, E.J., Hoekstra, J.B., Nieuwland, R., Gerdes, V.E. and Holleman, F. (2012) The Influence of Aspirin Dose and Glycemic Control on Platelet Inhibition in Patients with Type 2 Diabetes Mellitus. Journal of Thrombosis and Haemostasis, 10, 639-646. https://doi.org/10.1111/j.1538-7836.2012.04632.x
[25]
Muller, K.A., Chatterjee, M., Rath, D. and Geisler, T. (2015) Platelets, Inflammation and Anti-Inflammatory Effects of Antiplatelet Drugs in ACS and CAD. Thrombosis and Haemostasis, 114, 498-518. https://doi.org/10.1160/TH14-11-0947
[26]
Nagelschmitz, J., Blunk, M., Kraetzschmar, J., Ludwing, M., Wensig, G. and Holhfeld, T. (2014) Pharmacokinetics and Pharmacodynamics of Acetylsalicylic Acid after Intravenous and Oral Administration to Healthy Volunteers. Clinical Pharmacology: Advances and Applications, 6, 51-59. https://doi.org/10.2147/CPAA.S47895
[27]
Dzeshka, M.S., Shantsila, A. and Lip, G.Y.H. (2016) Effects of Aspirin on Endothelial Function and Hypertension. Current Hypertension Reports, 18, Article No. 83. https://doi.org/10.1007/s11906-016-0688-8
[28]
Grimaldi, R., Bisi, M., Lonni, E., Beggiato, E., Valpreda, A., Lococo, M.F., Dosio, E., Presutti, D.G., Tagliabue, M. and Gaita, F. (2014) Laboratory Aspirin Resistance Reversibility in Diabetic Patients: A Pilot Study Using Different Pharmaceutical Formulations. Cardiovascular Drugs and Therapy, 28, 323-329. https://doi.org/10.1007/s10557-014-6536-7
[29]
Abdin, A.A., Baalash, A.A. and Hamooda, H.E. (2010) Effects of Rosiglitazone and Aspirin on Experimental Model of Induced Type 2 Diabetes in Rats: Focus on Insulin Resistance and Inflammatory Markers. Journal of Diabetes and Its Complications, 24, 168-178. https://doi.org/10.1016/j.jdiacomp.2009.01.005
